雷贝拉唑钠在幽门螺杆菌阳性十二指肠溃疡患者中的应用效果

Application of Rabeprazole Sodium in Patients with Helicobacter Pylori Positive Duodenal Ulcer

目的:探讨以雷贝拉唑钠为中心的四联方案治疗幽门螺杆菌阳性十二指肠溃疡(DU)的临床效果。方法:选取2015年1月-2016年2月笔者所在医院消化内科收治的100例Hp阳性DU患者为研究对象。根据随机数字表法将其分为观察组(53例)和对照组(47例)。对照组患者给予传统四联疗法,即"奥美拉唑+阿莫西林+克拉霉素+枸橼酸铋钾"的四联方案;观察组质子泵抑制剂(PPI)替换为雷贝拉唑钠。疗程为14 d。对比两组患者的治疗有效率、Hp根除情况及不良反应发生情况。结果:观察组患者治疗总有效率明显高于对照组,差异有统计学意义(字2=7.231,P<0.05)。观察组患者Hp根除率为96.23%(51/53),明显高于对照组的80.85%(38/47),差异有统计学意义(字2=5.527,P<0.05)。两组均无因严重不良反应而中断治疗患者。结论:以雷贝拉唑钠为中心的四联方案治疗Hp阳性DU的效果显著,可提高Hp根除率,不良反应小,安全性高。

Objective:To investigate the clinical effect with Rabeprazole as the center in the treatment of Helicobacter pylori(Hp)positive duodenal ulcer(DU).Method:From January 2015 to February 2016,100 patients with Hp positive DU were enrolled in this study and were divided into observation group(53 cases)and control group(47 cases)according to the random number table method.In the control group,patients were treated with traditional quadruple therapy,namely“Omeprazole,Amoxicillin,Clarithromycin and Bismuth Potassium Citrate”;the Proton Pump Inhibitor(PPI)in the observation group was replaced with Rabeprazole Sodium.The course of treatment was 14 days.Compared the two groups of patients with the efficiency of treatment,Hp eradication and adverse reactions occurred.Result:The total effective rate of the treatment group was significantly higher than that of the control group(X2=7.231,P<0.05).The eradication rate of Hp in the observation group was 96.23%(51/53),which was significantly higher than 80.85%(38/47)in the control group,the difference was statistically significant(X2=5.527,P<0.05).None of the two groups discontinued treatment due to serious adverse events.Conclusion:The treatment of Hp-positive DU with Rabeprazole Sodium as the center is significant,and the eradication rate of Hp is high,the adverse reaction is small and the safety is high.